Abstract 446P
Background
Patients with cancer often develop cachexia. There has been no clearly effective treatment for this condition. However, anamorelin is approved for the treatment of cancer cachexia associated with advanced non-small cell lung cancer.
Methods
We conducted a retrospective analysis of treatment efficacy, adverse events and background factors in non-small cell lung cancer patients treated with anamorelin for cancer cachexia at our hospital from 1 April 2021 to 30 April 2023. Anamorelin effective cases were defined as those with improved performance status (PS) or appetite.
Results
A total of 68 patients were treated with anamorelin during the study period. The median age was 76.5 (59-92) years and the male patients were predominantly. Comorbidities included COPD (29.4%), interstitial pneumonia (22.1%). The clinical stage of lung cancer was stage 4 in 75.7% of patients. The median duration of anamorelin treatment was 36 (1-714) days. Anamorelin improved anorexia in 32 patients and PS in 21 patients. According to the definition of our study, there were 34 patients with anamorelin response and 34 patients without response. The patients with anamorelin response had a significantly longer duration of treatment (P<0.01) and significantly lower C-reactive protein (CRP) before treatment (P=0.04) compared to the patients without anamorelin response. The most common adverse events were nausea (14.7%), appetite loss (13.2%), hyperglycemia (11.8%) and liver damage (10.3%), respectively. Three patients experienced G3≤ adverse events. Fourteen (20.6%) patients discontinued anamorelin due to adverse events. The frequency of adverse events did not differ between the two groups.
Conclusions
Anamorelin improved appetite or PS in half of the patients in this retrospective study. In contrast, 14 (20.6 %) patients discontinued treatment due to adverse events. Anamorelin may be more effective in patients with lower CRP levels prior to treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T. Ito.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract